Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Advanced Composites
LeftNav
Aerospace
LeftNav
Amorphous Metal Structures
LeftNav
Analysis and Simulation
LeftNav
Asbestos and Substitutes
LeftNav
Associations, Research Organisations and Universities
LeftNav
Automation Equipment
LeftNav
Automotive
LeftNav
Biomaterials
LeftNav
Building Materials
LeftNav
Bulk Handling and Storage
LeftNav
CFCs and Substitutes
LeftNav
Company
LeftNav
Components
LeftNav
Consultancy
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Manufacturing Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
 
News

BTG to license innovative 'light-switchable' technology developed by Smith & Nephew

BTG : 24 April, 2001  (Company News)
BTG International, a world leader in technology transfer, has signed an agreement with Smith & Nephew, the global medical device company, to commercialise certain applications of Smith & Nephew's innovative light switchable adhesive technology.
The adhesives allow virtually pain-free removal of wound dressings and adhesive bandages. Conventional adhesives used to cover wounds can cause damage on removal, however, the new technology allows the adhesive to be 'de-activated' by peeling off a backing strip and exposing it to light for a number of seconds. The dressing can then be removed without trauma to the patient or the wound.

LSAs are believed to have potential outside the wound-care applications in such areas as transdermal drug delivery systems (e.g. nicotine patches), medical electrodes/tapes and other non-medical areas. The technology was developed by Dr Ian Webster at Smith & Nephew's Group Research Centre in York, UK.

'Opportunities to apply the technology outside wound-care certainly exist.' commented Dr Gareth Lloyd-Jones, Managing Director of Smith & Nephew's Group Research Centre. 'To fully realise the further potential of the technology, we believe a more focused approach is necessary and that BTG can provide the best means of achieving this.'

Martin Sandford, Director of Operations for BTG's Health Medical and BioTechnologies Division, said: 'BTG is delighted to be commercialising this technology and several major companies have already expressed an interest in its possibilities. BTG works with a variety of organisations to maximise the value of its intellectual property assets by out-licensing, taking on the associated risk and expense of accessing non-core technology applications and sharing the royalties generated with the source.'

BTG is currently looking for companies with an interest in novel/advanced adhesives to commercialise this opportunity fully. Licences are available for some medical and all non-medical applications.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 NewMaterials.com
Netgains Logo